Bae and coworkers screened 713 colorectal cancers for CDX2 expression using immunohistochemistry (IHC) and discovered that about 6% of these tumors exhibited CDX2 loss: at the histological level, CDX2 loss was associated with poor differentiation, an increased number of tumor-infiltrating lymphocytes, luminal serration and mucin production, and at the molecular level, CDX2 loss was associated with CIMP-H, MSI-H and BRAF mutations [87]. Here, BRAF is linked to neoplasm.